Intuitive Surgical, the leader in surgical robotics, has fallen 30% from early 2025 highs but is poised for a technical breakout ahead of its Q3 earnings release on October 20. With strong fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and ~43% upside potential to all-time highs, the stock earns a Zacks Rank #2 (Buy) rating. The company projects 15% Q3 revenue growth and 17% revenue growth for 2026.

Q3 earnings season shows mixed results with early reports tracking modestly below recent quarters. Import prices hit their highest rate since May at +1.1%, signaling persistent inflation concerns. The New York Fed's October Services report plummeted to -20.7, marking the sharpest decline since March. Key earnings this week included Travelers beating expectations with a +29.84% earnings surprise, while regional banks showed modest beats. Major tech and consumer companies including Netflix, Tesla, Meta, and General Motors are set to report next week.

Q3 earnings season shows mixed results with early reports tracking modestly below recent quarters. Import prices rose higher than expected in September (+1.1% vs +0.8% expected), marking the highest rate since May. The NY Fed's October Services report came in significantly below expectations at -20.7 vs -4.1 expected, hitting its lowest level since March. Among earnings reports, Travelers beat estimates by 29.84%, while regional banks Regions Financial, Citizens Financial Group, and M&T Bank also beat earnings expectations. Major tech earnings from Netflix, Tesla, Meta, and others are expected next week.

Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment.

Intuitive Surgical (ISRG) outperformed the broader market on October 15, 2026, closing up 1.81% and gaining 9.93% over the past month. The company has a Zacks Rank #2 (Buy) rating with expected Q3 EPS growth of 8.75% and full-year earnings growth of 20.27%. However, the stock trades at a premium valuation with a Forward P/E of 39.15 compared to the industry average of 23.25.

Intuitive Surgical (ISRG) has gained nearly 12% in a month, outperforming the market ahead of Q3 earnings. The company benefits from strong da Vinci 5 adoption, growing Ion procedures, and expanding international markets. However, slower U.S. procedure growth, GLP-1 drug competition affecting bariatric procedures, and China headwinds pose risks. ISRG trades at a premium 36.04X forward P/E but remains attractive with a Zacks Rank #2 (Buy) rating.

Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption.

Intuitive Surgical (ISRG) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $10.74 per share, with analysts raising estimates by 3.5% over the past three months. The upgrade positions ISRG in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

Intuitive Surgical (ISRG) has been heavily searched on Zacks.com and has outperformed the broader market with a +13.2% return over the past month. The company holds a Zacks Rank #2 (Buy) rating based on strong earnings estimate trends, with expected earnings growth of +20.3% for the current fiscal year and +11.6% for the next year. Revenue is projected to grow +16.7% and +12.5% respectively. However, the stock trades at a premium valuation (D grade) compared to peers.

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

Intuitive Surgical (ISRG) outperformed the S&P 500 with a +2.06% daily gain, reaching $423.96. The stock has gained 15.24% prior to trading and is expected to report Q3 earnings on October 20, 2026, with forecasted EPS of $2.61 (+8.75% YoY) and revenue of $2.88 billion (+14.98% YoY). However, the stock trades at a premium valuation with a Forward P/E of 38.7 versus the industry average of 22.63, and holds a Zacks Rank of #3 (Hold).